Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.89
TKPYY's Cash to Debt is ranked higher than
61% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. TKPYY: 0.89 )
TKPYY' s 10-Year Cash to Debt Range
Min: 0.39   Max: No Debt
Current: 0.89

Equity to Asset 0.55
TKPYY's Equity to Asset is ranked higher than
63% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. TKPYY: 0.55 )
TKPYY' s 10-Year Equity to Asset Range
Min: 0.55   Max: 0.78
Current: 0.55

0.55
0.78
F-Score: 5
Z-Score: 2.33
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Revenue Growth (%) -100.00
TKPYY's Revenue Growth (%) is ranked lower than
57% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. TKPYY: -100.00 )
TKPYY' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 11.6
Current: -100

-100
11.6
EBITDA Growth (%) -19.90
TKPYY's EBITDA Growth (%) is ranked higher than
54% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. TKPYY: -19.90 )
TKPYY' s 10-Year EBITDA Growth (%) Range
Min: -33.9   Max: 24.8
Current: -19.9

-33.9
24.8
EPS Growth (%) -24.50
TKPYY's EPS Growth (%) is ranked higher than
57% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. TKPYY: -24.50 )
TKPYY' s 10-Year EPS Growth (%) Range
Min: -24.5   Max: 31.4
Current: -24.5

-24.5
31.4
» TKPYY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

TKPYY Guru Trades in

TKPYY Guru Trades in

TKPYY Guru Trades in

Q3 2012

TKPYY Guru Trades in Q3 2012

Vanguard Health Care Fund 5,599,900 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with TKPYY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.40
TKPYY's P/E(ttm) is ranked higher than
73% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.60 vs. TKPYY: 33.40 )
TKPYY' s 10-Year P/E(ttm) Range
Min: 7.81   Max: 72.77
Current: 33.4

7.81
72.77
P/B 1.50
TKPYY's P/B is ranked higher than
85% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.42 vs. TKPYY: 1.50 )
TKPYY' s 10-Year P/B Range
Min: 1.19   Max: 1.83
Current: 1.5

1.19
1.83
P/S 2.19
TKPYY's P/S is ranked higher than
71% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.45 vs. TKPYY: 2.19 )
TKPYY' s 10-Year P/S Range
Min: 1.67   Max: 12.29
Current: 2.19

1.67
12.29
PFCF 19.10
TKPYY's PFCF is ranked higher than
89% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TKPYY: 19.10 )
TKPYY' s 10-Year PFCF Range
Min: 8.24   Max: 157.48
Current: 19.1

8.24
157.48
EV-to-EBIT 22.42
TKPYY's EV-to-EBIT is ranked higher than
81% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. TKPYY: 22.42 )
TKPYY' s 10-Year EV-to-EBIT Range
Min: 5.5   Max: 78.6
Current: 22.42

5.5
78.6
Shiller P/E 17.20
TKPYY's Shiller P/E is ranked higher than
91% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TKPYY: 17.20 )
TKPYY' s 10-Year Shiller P/E Range
Min: 10.16   Max: 18.34
Current: 17.2

10.16
18.34
Current Ratio 2.07
TKPYY's Current Ratio is ranked higher than
64% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. TKPYY: 2.07 )
TKPYY' s 10-Year Current Ratio Range
Min: 1.21   Max: 4
Current: 2.07

1.21
4
Quick Ratio 1.71
TKPYY's Quick Ratio is ranked higher than
69% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.77 vs. TKPYY: 1.71 )
TKPYY' s 10-Year Quick Ratio Range
Min: 1   Max: 3.64
Current: 1.71

1
3.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.67
TKPYY's Dividend Yield is ranked higher than
90% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. TKPYY: 1.67 )
TKPYY' s 10-Year Dividend Yield Range
Min: 1.55   Max: 5.32
Current: 1.67

1.55
5.32
Dividend Payout 0.57
TKPYY's Dividend Payout is ranked higher than
72% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TKPYY: 0.57 )
TKPYY' s 10-Year Dividend Payout Range
Min: 0.8   Max: 6.61
Current: 0.57

0.8
6.61
Dividend growth (3y) -2.00
TKPYY's Dividend growth (3y) is ranked higher than
74% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -0.10 vs. TKPYY: -2.00 )
TKPYY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: -1.8
Current: -2

Yield on cost (5-Year) 1.51
TKPYY's Yield on cost (5-Year) is ranked higher than
81% of the 465 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.38 vs. TKPYY: 1.51 )
TKPYY' s 10-Year Yield on cost (5-Year) Range
Min: 1.38   Max: 4.74
Current: 1.51

1.38
4.74

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.60
TKPYY's Price/Tangible Book is ranked higher than
50% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. TKPYY: 6.60 )
TKPYY' s 10-Year Price/Tangible Book Range
Min: 1.8   Max: 7.51
Current: 6.6

1.8
7.51
Price/DCF (Projected) 0.90
TKPYY's Price/DCF (Projected) is ranked higher than
96% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.80 vs. TKPYY: 0.90 )
TKPYY' s 10-Year Price/DCF (Projected) Range
Min: 0.45   Max: 0.96
Current: 0.9

0.45
0.96
Price/Median PS Value 1.30
TKPYY's Price/Median PS Value is ranked higher than
57% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. TKPYY: 1.30 )
TKPYY' s 10-Year Price/Median PS Value Range
Min: 0.82   Max: 5.24
Current: 1.3

0.82
5.24
Price/Graham Number 3.10
TKPYY's Price/Graham Number is ranked higher than
67% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. TKPYY: 3.10 )
TKPYY' s 10-Year Price/Graham Number Range
Min: 0.95   Max: 3.3
Current: 3.1

0.95
3.3
Earnings Yield (Greenblatt) 4.50
TKPYY's Earnings Yield (Greenblatt) is ranked higher than
68% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. TKPYY: 4.50 )
TKPYY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 18.2
Current: 4.5

1.3
18.2
Forward Rate of Return (Yacktman) -6.74
TKPYY's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. TKPYY: -6.74 )
TKPYY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.5   Max: 109.5
Current: -6.74

-7.5
109.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:4502.Japan, 4502.Japan, TKD.Germany
Takeda Pharmaceutical Co., Ltd is engaged in the manufacturing, marketing and import and export of pharmaceutical drugs.
» More Articles for OTCPK:TKPYY

Headlines

Articles On GuruFocus.com
Don't Quit on Teva Just Yet Feb 20 2014 
Soros´ Bet on Teva’s Transition (A Transition for Better or for Worse?) Dec 18 2013 
T. Rowe Price Japan Fund Top 5 New Buys Oct 17 2013 


More From Other Websites
AstraZeneca's Gout Drug in Focus with Phase III Data Readout Aug 15 2014
Alnylam's Q2 Loss Wider-than-Expected, Pipeline in Focus Aug 11 2014
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount Aug 08 2014
Seattle Genetics Up on Narrower-than-Expected Q2 Loss Aug 04 2014
AMAG Pharmaceuticals Q2 Loss Narrows as Feraheme Sales Rise Jul 30 2014
J&J's Velcade in Focus at the European Hematology Association Jun 17 2014
Orexigen Slumps as Obesity Drug Approval Delayed Jun 12 2014
Orexigen's Upcoming Pipeline Catalyst Jun 09 2014
MacroGenics, Takeda Enter Strategic Alliance to Develop DART May 27 2014
FDA approves Entyvio for ulcerative colitis, Crohn's disease May 20 2014
Jury finds Takeda not liable for death of patient on Actos, Bloomberg reports May 15 2014
Prothena: 4 Different Insiders Have Purchased Shares This Month May 13 2014
Alnylam Up on Narrower-than-Expected Q1 Loss May 12 2014
Wider-than-Expected Loss at Orexigen in Q1 May 12 2014
Wider-than-Expected Q1 Loss at AMAG Apr 25 2014
Seattle Genetics Earns Milestone Payment Apr 09 2014
Takeda Pharmaceutical Company Limited -- Moody's affirms Takeda's Aa3 rating: outlook stable Apr 09 2014
Wall Street Breakfast: Must-Know News Apr 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide